Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Explore existing data to uncover cancer risk insights, seeking to understand outcomes like survival and treatment response.
Funder: National Institutes of Health
Due Dates: June 5, 2025 (New R01) | July 5, 2025 (Renewal/Resubmission/Revision R01) | October 5, 2025 (New R01) | November 5, 2025 (Renewal/Resubmission/Revision R01) | February 5, 2026 (New R01) | March 5, 2026 (Renewal/Resubmission/Revision R01) | June 5, 2026 (New R01) | July 5, 2026 (Renewal/Resubmission/Revision R01) | October 5, 2026 (New R01, final) | November 5, 2026 (Renewal/Resubmission/Revision R01, final) | November 6, 2026 (NOFO expiration)
Funding Amounts: Up to $350,000 direct costs per year, for a maximum of 5 years (R01 mechanism).
Summary: Supports secondary analysis and integration of existing data to elucidate cancer risk and related outcomes without new clinical trials.
Key Information: Clinical trials are not allowed; only secondary data analysis and limited data generation (≤10% of budget).
Description
This NIH funding opportunity supports research projects that conduct secondary analysis and integration of existing datasets to advance understanding of cancer risk and related outcomes, such as risk prediction, survival, or response to treatment. The initiative encourages innovative use of diverse data sources—including clinical, environmental, genomic, behavioral, and health services data—to address key scientific questions relevant to cancer. Projects may involve new research aims using existing data, development or application of advanced analytical methods, or novel integration of datasets. The program specifically excludes clinical trials and the collection or generation of new data, except for limited validation purposes (up to 10% of the budget).
